These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30910272)

  • 1. Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag.
    Lázaro Salvador M; Escribano Subías P; Rodriguez Padial L
    Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):393-394. PubMed ID: 30910272
    [No Abstract]   [Full Text] [Related]  

  • 2. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.
    El-Kersh K; Smith JS
    Am J Ther; 2017; 24(5):e620-e621. PubMed ID: 27574945
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
    Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
    BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
    Thurber KM; Williams BM; Bates RE; Frantz RP
    Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
    Hardin EA; Chin KM
    Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral treprostinil in the treatment of pulmonary arterial hypertension.
    Feldman J; Habib N; Radosevich J; Dutt M
    Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selexipag (Uptravi) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2016 Feb; 58(1488):21-3. PubMed ID: 26859660
    [No Abstract]   [Full Text] [Related]  

  • 12. Selexipag for the treatment of pulmonary arterial hypertension.
    Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
    Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Center Experience Using Selexipag in a Pediatric Population.
    Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
    Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Koo R; Lo J; Bock MJ
    Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
    Lázaro Salvador M; Akerström F; Escribano Subías P; Berenguel Senén A; Martinez Mateo V; Rodriguez Padial L
    Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):102-103. PubMed ID: 30060983
    [No Abstract]   [Full Text] [Related]  

  • 17. An evaluation of selexipag for the treatment of pulmonary hypertension.
    Panagiotidou E; Boutou A; Pitsiou G
    Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pulmonary hypertension].
    Kovacs G; Olschewski H
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2026-8. PubMed ID: 23023615
    [No Abstract]   [Full Text] [Related]  

  • 19. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selexipag for the treatment of pulmonary arterial hypertension.
    Skoro-Sajer N; Lang IM
    Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.